¼¼°èÀÇ Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° - »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2024-2031³â)
Vascular Endothelial Growth Factor Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
Ç÷°ü³»ÇǼºÀåÀÎÀÚ(VEGF) ½ÃÀåÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú ´Ù¾çÇÑ Ç÷°ü °ü·Ã Áúȯ ¹× »óŸ¦ Ä¡·áÇϱâ À§ÇÑ È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ±Ù ¸î ³âµ¿¾È Å« °ßÀÎÂ÷ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¿ªÇп¡ ´ëÇØ ÀÚ¼¼È÷ Á¶»çÇÏ°í ½ÃÀå ±Ô¸ð, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, °æÀï ȯ°æ¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» ´ã°í ÀÖ½À´Ï´Ù. ºÐ¼® ±â°£Àº 2024³âºÎÅÍ 2031³â±îÁöÀ̸ç, ÀÌÇØ°ü°èÀڵ鿡°Ô Àü·«Àû ÀÇ»ç°áÁ¤°ú »ç¾÷ ¼ºÀå¿¡ µµ¿òÀÌ µÇ´Â ±ÍÁßÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è VEGF ½ÃÀåÀº 2024-2031³â CAGR 10.7%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024³â ½ÃÀå ±Ô¸ð´Â 2¾ï 6,170¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç 2031³â¿¡´Â 5¾ï 3,311¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
- ½ÃÀå °¡Ä¡ ÃßÁ¤Ä¡(2024³â) : 2¾ï 6,170¸¸ ´Þ·¯
- ¿¹»ó ½ÃÀå °¡Ä¡(2031³â) : 5¾ï 3,311¸¸ ´Þ·¯
- ¼¼°è ½ÃÀå ¼ºÀå·ü(2024-2031³â CAGR) : 10.7%.
VEGF ½ÃÀå - º¸°í¼ ¹üÀ§ :
ÀÌ Á¶»ç º¸°í¼´Â VEGF ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÏ°í ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ» °Á¶Çϸç, VEGF´Â »õ·Î¿î Ç÷°üÀ» Çü¼ºÇÏ´Â °úÁ¤ÀÎ Ç÷°ü½Å»ý¿¡¼ ±× ¿ªÇÒ·Î ÀÎÇØ Ç×¾Ï Ä¡·áÀÇ Áß¿äÇÑ Ç¥ÀûÀÔ´Ï´Ù. Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ À¯ÇüÀÇ ¾Ï°ú ³ëÈ °ü·Ã Ȳ¹Ýº¯¼º(AMD), ´ç´¢¸Á¸·º´Áõ ¹× ±âŸ ¸Á¸· ÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¾Ï°ú ³ëÈ °ü·Ã ÁúȯÀÇ ¹ß»ý·ü Áõ°¡¿Í ÀÇÇÐ ¿¬±¸ ¹× Ä¡·á¹ýÀÇ ¹ßÀüÀº VEGF Ç¥Àû Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·ü Áõ°¡´Â VEGF ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. ¾Ï¼¼Æ÷ÀÇ ¼ºÀå°ú ÀüÀÌ¿¡ »õ·Î¿î Ç÷°üÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ç× VEGF Ä¡·á´Â ´Ù¾çÇÑ ¾Ï Ä¡·áÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AMD¿Í °°Àº ³ëÈ °ü·Ã ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾à¹° Àü´Þ ½Ã½ºÅÛ ¹× °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ ±â¼ú ¹ßÀüÀº º¸´Ù È¿°úÀûÀ̰í Ç¥ÀûÈµÈ Ä¡·á¹ýÀ¸·Î À̾îÁ® ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Ä¡·á¹ý °³¼±°ú VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí VEGF ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·á´Â °í°¡À̱⠶§¹®¿¡ ƯÈ÷ ÀÇ·á ½Ã½ºÅÛÀÌ ¹ß´ÞÇÏÁö ¾ÊÀº Áö¿ª¿¡¼´Â ÀϺΠȯÀÚÀÇ Á¢±Ù¼ºÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, VEGF ¾ïÁ¦Á¦ÀÇ ºÎÀÛ¿ëÀº °íÇ÷¾Ð, »óó Ä¡À¯ Àå¾Ö¿Í °°Àº ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ ȯÀÚ¿¡°Ô À§ÇèÀ» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ À庮°ú ±ä ½ÂÀÎ ÀýÂ÷µµ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ´ëü ¿ä¹ý°úÀÇ °æÀï°ú °áÇÕÇÏ¿© ½ÃÀå È®´ë¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
VEGF ½ÃÀå¿¡´Â ¼ºÀå°ú Çõ½ÅÀÇ Å« ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç× VEGF Ä¡·áÁ¦ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× Á¦³×¸¯ ÀǾàǰÀÇ °³¹ßÀº ´õ Àú·ÅÇÑ Ä¡·á¹ýÀÇ ±æÀ» ¿¾î ´õ ¸¹Àº ȯÀÚ±º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®´ëÇϰí, VEGF ¾ïÁ¦Á¦ÀÇ »õ·Î¿î Ä¡·á ¿ëµµ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸´Â ½ÃÀå ´Ù°¢È °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¦¾àȸ»ç¿Í ¿¬±¸±â°üÀÇ °øµ¿¿¬±¸´Â ȹ±âÀûÀÎ Ä¡·á¹ýÀ» âÃâÇϰí VEGF ½ÃÀåÀÇ Àúº¯À» È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÷´Ü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â ½ÅÈï ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ´Â ½ÃÀå È®´ëÀÇ ¶Ç ´Ù¸¥ ±âȸÀÔ´Ï´Ù.
º» º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®µé
- 2024-2031³â VEGF ½ÃÀåÀÇ ¿¹»ó CAGRÀº?
- VEGF ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
- VEGF ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ªÀº?
- ¼¼°è VEGF ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?
- VEGF ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ±âȸ´Â?
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
- ½ÃÀå ¹üÀ§/ ºÐ·ù
- ½ÃÀåÀÇ Á¤ÀÇ/¹üÀ§/Á¦ÇÑ
- Æ÷ÇÔ°ú Á¦¿Ü
Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ
- ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
- Á¦Ç° Çõ½Å/°³¹ß µ¿Çâ
Á¦4Àå ÁÖ¿ä ³»¿ë
- ÃÑÀÌÀÍ ºÐ¼®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- ¹ë·ùüÀÎ ºÐ¼®
- VEGF ½ÃÀå ¸ÅÃâ ºñ±³(2019³â°ú 2023³â)
Á¦5Àå ½ÃÀå ¹è°æ
- °Å½Ã°æÁ¦ ¿äÀÎ
- ¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
- ½ÃÀå ¿ªÇÐ
Á¦6Àå COVID-19 À§±â ºÐ¼®
- COVID-19ÇöÀç Åë°è¿Í ÇâÈÄ ¿µÇâ °¡´É¼º
- ÇöÀç GDP ¿¹ÃøÀ̶ó°í ¿¹»óµÇ´Â ¿µÇâ
- 2008³â°ú ºñ±³ÇÑ ÇöÀç °æÁ¦ ¿¹Ãø °æÁ¦ ºÐ¼®
- COVID-19·Î ¿µÇ⠺м®
- VEGF À¯Çüº°
- VGEF ¿ëµµº°
- VEGF ¹ßÇö ¼÷ÁÖº°
- ÃÖÁ¾»ç¿ëÀÚº°
- Áö¿ªº°
- 2023³â ½ÃÀå ½Ã³ª¸®¿À
Á¦7Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ¼ö¿ä(±Ý¾× ¶Ç´Â ±Ô¸ð) ºÐ¼®
- °ú°Å ½ÃÀå ¸ÅÃ⠺м®(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ¸ÅÃâ ¿¹Ãø(2024³â-2031³â)
- Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
- Àý´ëÀû ÀÌÀÍ ±âȸ ºÐ¼®
Á¦8Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VEGF À¯Çüº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : VEGF À¯Çüº°(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : VEGF À¯Çüº°(2024³â-2032³â)
- Àΰ£ VEGF
- Áã VEGF
- Åä³¢ VEGF
- ·¡Æ® VEGF
- ±âŸ
- VEGF À¯Çüº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦9Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : VGEF ¿ëµµº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : VGEF ¿ëµµº°(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : VGEF ¿ëµµº°(2024³â-2032³â)
- ¼¼Æ÷¹è¾ç
- ¼¼Æ÷ ±â¹Ý Ä¡·á
- ÀǾàǰ °³¹ß
- À¯ÀüÀÚ Ä¡·á
- Èñ±ÍÁúȯ Ä¡·á
- º´¿ë¿ä¹ý
- â»ó Ä¡À¯ ¿¬±¸
- Ç÷¾×ÇÐ ¿¬±¸
- »À Çü¼º
- Ç×Ç÷°ü ½Å»ý ¿ä¹ý
- VGEF ¿ëµµº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦10Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ¹ßÇö ¼÷ÁÖº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ¹ßÇö ¼÷ÁÖº°(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : ¹ßÇö ¼÷ÁÖº°(2024³â-2032³â)
- HEK293 ¼¼Æ÷
- ´ëÀå±Õ
- °ïÃæ ¼¼Æ÷
- CHO
- NS0
- ±âŸ
- ¹ßÇö ¼÷ÁÖº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦11Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
- ¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024³â-2032³â)
- Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- ¿¬±¸¼¾ÅÍ ¹× Çмú±â°ü
- CMO/CDMO
- ±âŸ ÃÖÁ¾»ç¿ëÀÚ
- ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦12Àå ¼¼°èÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼® : Áö¿ªº°
- ¼·Ð
- °ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(2019³â-2023³â)
- ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð ºÐ¼®¡¤¿¹Ãø : Áö¿ªº°(2024³â-2032³â)
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ³²¾Æ½Ã¾Æ
- µ¿¾Æ½Ã¾Æ
- ¿À¼¼¾Æ´Ï¾Æ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áö¿ªº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦13Àå ºÏ¹ÌÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦14Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦15Àå À¯·´ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦16Àå ³²¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦17Àå µ¿¾Æ½Ã¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦18Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦19Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)ÀÇ Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ(VEGF) ½ÃÀå ºÐ¼®
Á¦20Àå ½ÃÀå ±¸Á¶ ºÐ¼®
- ±â¾÷ °èÃþº° ½ÃÀå ºÐ¼®
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
- ½ÃÀå ÀÔÁö ºÐ¼®
Á¦21Àå °æÀï ºÐ¼®
- °æÀï ´ë½Ãº¸µå
- °æÀï º¥Ä¡¸¶Å·
- °æÀï ±¸µµ
- Thermo Fisher Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Bio-Techne(R&D Systems, Inc.)
- GenScript
- Miltenyi Biotec.
- Abcam PLC.
- Sino Biological Inc.
- Cell Signaling Technology, Inc.
- ACROBiosystems
- STEMCELL Technologies
- Creative Bioarray
- PeproTech
- Applied Biological Materials(abm) Inc.
- GenWay Biotech
- Leadgene Biomedical, Inc.
- Boster Bio
- Prospec-Tany Technogene Ltd.
- Proteintech Group, Inc
Á¦22Àå »ç¿ëµÈ ÀüÁ¦Á¶°Ç°ú µÎÀÚ¾î
Á¦23Àå Á¶»ç ¹æ¹ý
LSH
The Vascular Endothelial Growth Factor (VEGF) market has gained significant traction in recent years, driven by advances in medical research and the growing need for effective therapies to treat a range of vascular-related diseases and conditions. This comprehensive report from Persistence Market Research delves into the dynamics of the VEGF market, providing key insights into market size, growth drivers, challenges, opportunities, and competitive landscape. The analysis covers the period from 2024 to 2031, offering stakeholders valuable information to guide their strategic decisions and business growth.
The global VEGF market is projected to expand at a CAGR of 10.7% from 2024 to 2031, with a market value estimated at USD 261.7 million in 2024 and expected to reach USD 533.1 million by 2031.
Key Insights:
- Market Value Estimate (2024): USD 261.7 Million
- Projected Market Value (2031): USD 533.1 Billion
- Global Market Growth Rate (CAGR 2024 to 2031): 10.7%
VEGF Market - Report Scope:
The report provides a comprehensive analysis of the VEGF market, highlighting key factors driving growth. VEGF is a significant target for anti-cancer therapies due to its role in angiogenesis, the process of forming new blood vessels. Anti-VEGF therapies are used to treat various types of cancers, as well as other conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. The growing incidence of cancer and age-related diseases, coupled with advancements in medical research and treatment methods, has fueled demand for VEGF-targeting therapies.
Market Growth Drivers:
The increasing prevalence of cancer worldwide is a major driver for the VEGF market. As cancer cells require new blood vessels to grow and spread, anti-VEGF therapies have become a cornerstone in the treatment of various cancers. Additionally, the rising incidence of age-related diseases, such as AMD, has further contributed to market growth. Technological advancements in drug delivery systems and personalized medicine approaches have led to more effective and targeted therapies, fostering market expansion. The demand for improved treatments and the development of new applications for VEGF inhibitors are key factors driving the market's growth.
Market Restraints:
Despite its potential, the VEGF market faces certain challenges. The high cost of anti-VEGF therapies can limit access for some patients, especially in regions with less developed healthcare systems. Additionally, side effects associated with VEGF inhibitors, such as hypertension and impaired wound healing, can pose risks to patients. Regulatory hurdles and the lengthy process of drug approval also impact market growth. These factors, combined with competition from alternative therapies, can restrain the market's expansion.
Market Opportunities:
The VEGF market presents significant opportunities for growth and innovation. The development of biosimilars and generic versions of anti-VEGF therapies offers a pathway to more affordable treatments, expanding access to a broader patient base. Ongoing research into new therapeutic applications for VEGF inhibitors provides potential for market diversification. Furthermore, collaborations between pharmaceutical companies and research institutions can lead to groundbreaking treatments and expand the VEGF market's reach. Investment in emerging markets, where demand for advanced therapies is growing, represents another opportunity for market expansion.
Key Questions Addressed in the Report:
- What is the expected CAGR for the VEGF market between 2024 and 2031?
- What are the major factors driving growth in the VEGF market?
- Which regions hold the largest share of the VEGF market?
- Who are the key players in the global VEGF market?
- What are the main opportunities for growth in the VEGF market?
Competitive Landscape and Business Strategies:
The VEGF market features a competitive landscape with leading players like Genentech, Regeneron Pharmaceuticals, and Amgen. These companies focus on innovation, research and development, and strategic collaborations to maintain their market position. Genentech's Avastin, a widely used anti-VEGF drug, is a prominent example of a successful product in this sector. Regeneron Pharmaceuticals has also gained a significant market share with its product Eylea, used in the treatment of AMD and other retinal diseases.
Key business strategies include the development of new drug formulations, expansion into new therapeutic areas, and partnerships with other pharmaceutical companies. Companies are also focusing on expanding their presence in emerging markets and exploring biosimilar opportunities to increase their market reach.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Bio-Techne [R&D Systems, Inc.]
- GenScript
- Miltenyi Biotec.
- Abcam PLC.
- Sino Biological Inc.
- Cell Signaling Technology, Inc.
- ACROBiosystems
- STEMCELL Technologies
VEGF Market Segmentation:
VEGF Market by VEGF Type:
- Human VEGF
- Mouse VEGF
- Rat VEGF
- Rabbit VEGF
- Others VEGF
VEGF Market by Expression Host:
- CHO
- E. Coli
- HEK
- NSO
- Insect Cells
- Others
VEGF Market by Application:
- Cell Culture
- Cell-based Therapy
- Drug Development
- Gene Therapy
- Rare Disease treatment
- Wound Healing Research
- Combination Therapies
- Hematology Research
- Osteogenesis
- Anti-Angiogenic Therapy
VEGF Market by End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- CMOs & CDMOs
- Other End Users
Research Centers & Laboratories
Hospital-attached Laboratories (HALs)
VEGF Market by Region:
- North America VEGF Market
- Latin America VEGF Market
- Europe VEGF Market
- South Asia VEGF Market
- East Asia VEGF Market
- Oceania VEGF Market
- Middle East & Africa VEGF Market
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand Side Trends
- 1.3. Supply Side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusion And Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
4. Key Inclusions
- 4.1. Gross Margin Analysis
- 4.2. Regulatory Scenario
- 4.3. Value Chain Analysis
- 4.4. VEGF Market Value Comparison 2019 and 2023
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Spending Outlook
- 5.1.3. Global Growth Factor Market Outlook
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Advancements in Protein Characterization Techniques
- 5.2.2. Increase in R&D Funding and Grants
- 5.2.3. High Prevalence of Chronic Diseases
- 5.2.4. New Product Launch
- 5.2.5. Rising Research Activities for Rare Disease Indications
- 5.2.6. Emergence of Novel Patented Technologies
- 5.2.7. Collaborations and Agreements between Manufacturers
- 5.2.8. Regulatory Approvals
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
- 6.1. Current COVID-19 Statistics and Probable Future Impact
- 6.2. Current GDP Projection and Probable Impact
- 6.3. Current Economic Projection as compared to 2008 Economic analysis
- 6.4. COVID-19 and Impact Analysis
- 6.4.1. By VEGF Types
- 6.4.2. By VGEF Application
- 6.4.3. By VEGF Expression Hosts
- 6.4.4. By End User
- 6.4.5. By Region
- 6.5. 2023 Market Scenario
7. Global Vascular Endothelial Growth Factor (VEGF) Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031
- 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
- 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis
8. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Types
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Mn) Analysis By VEGF Types, 2019-2023
- 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VEGF Types, 2024-2031
- 8.3.1. Human VEGF
- 8.3.2. Mouse VEGF
- 8.3.3. Rabbit VEGF
- 8.3.4. RAT VEGF
- 8.3.5. Others
- 8.4. Market Attractiveness Analysis By VEGF Types
9. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VGEF Application
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Mn) Analysis By VGEF Application, 2019-2023
- 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Application, 2024-2031
- 9.3.1. Cell Culture
- 9.3.2. Cell-Based Therapy
- 9.3.3. Drug Development
- 9.3.4. Gene Therapy
- 9.3.5. Rare Disease Treatment
- 9.3.6. Combination Therapies
- 9.3.7. Wound Healing Research
- 9.3.8. Hematology Research
- 9.3.9. Osteogenesis
- 9.3.10. Anti-Angiogenic Therapy
- 9.4. Market Attractiveness Analysis By VGEF Application
10. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Expression Hosts
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Mn) Analysis By VGEF Expression Hosts, 2019-2023
- 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Expression Hosts, 2024-2031
- 10.3.1. HEK293 cells
- 10.3.2. E. coli
- 10.3.3. Insect Cells
- 10.3.4. CHO
- 10.3.5. NS0
- 10.3.6. Others
- 10.4. Market Attractiveness Analysis By VGEF Expression Hosts
11. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by End User
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
- 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
- 11.3.1. Pharmaceutical and Biotechnology Companies
- 11.3.2. Research Centers & Academic Institutes
- 11.3.3. CMO and CDMO
- 11.3.4. Other End Users
- 11.3.4.1. Research laboratories
- 11.3.4.2. Hospital-Attached laboratories (HALs)
- 11.4. Market Attractiveness Analysis By End User
12. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by Region
- 12.1. Introduction
- 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
- 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. South Asia
- 12.3.5. East Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa
- 12.4. Market Attractiveness Analysis By Region
13. North America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 13.1. Introduction
- 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 13.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 13.3.1. By Country
- 13.3.1.1. U.S.
- 13.3.1.2. Canada
- 13.3.2. By VEGF Types
- 13.3.3. By VGEF Application
- 13.3.4. By VGEF Expression Hosts
- 13.3.5. By End User
- 13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By VEGF Types
- 13.4.3. By VGEF Application
- 13.4.4. By VGEF Expression Hosts
- 13.4.5. By End User
- 13.5. Key Market Participants - Intensity Mapping
- 13.6. Drivers and Restraints - Impact Analysis
- 13.7. Country Level Analysis & Forecast
- 13.7.1. U.S. Vascular Endothelial Growth Factor (VEGF) Market
- 13.7.1.1. Introduction
- 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.7.1.2.1. By VEGF Types
- 13.7.1.2.2. By VGEF Application
- 13.7.1.2.3. By VGEF Expression Hosts
- 13.7.1.2.4. By End User
- 13.7.2. Canada Vascular Endothelial Growth Factor (VEGF) Market
- 13.7.2.1. Introduction
- 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.7.2.2.1. By VEGF Types
- 13.7.2.2.2. By VGEF Application
- 13.7.2.2.3. By VGEF Expression Hosts
- 13.7.2.2.4. By End User
14. Latin America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 14.1. Introduction
- 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 14.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 14.3.1. By Country
- 14.3.1.1. Brazil
- 14.3.1.2. Mexico
- 14.3.1.3. Argentina
- 14.3.1.4. Rest of Latin America
- 14.3.2. By VEGF Types
- 14.3.3. By VGEF Application
- 14.3.4. By VGEF Expression Hosts
- 14.3.5. By End User
- 14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By VEGF Types
- 14.4.3. By VGEF Application
- 14.4.4. By VGEF Expression Hosts
- 14.4.5. By End User
- 14.5. Key Market Participants - Intensity Mapping
- 14.6. Drivers and Restraints - Impact Analysis
- 14.7. Country Level Analysis & Forecast
- 14.7.1. Brazil Vascular Endothelial Growth Factor (VEGF) Market
- 14.7.1.1. Introduction
- 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.7.1.2.1. By VEGF Types
- 14.7.1.2.2. By VGEF Application
- 14.7.1.2.3. By VGEF Expression Hosts
- 14.7.1.2.4. By End User
- 14.7.2. Argentina Vascular Endothelial Growth Factor (VEGF) Market
- 14.7.2.1. Introduction
- 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.7.2.2.1. By VEGF Types
- 14.7.2.2.2. By VGEF Application
- 14.7.2.2.3. By VGEF Expression Hosts
- 14.7.2.2.4. By End User
- 14.7.3. Mexico Vascular Endothelial Growth Factor (VEGF) Market
- 14.7.3.1. Introduction
- 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.7.3.2.1. By VEGF Types
- 14.7.3.2.2. By VGEF Application
- 14.7.3.2.3. By VGEF Expression Hosts
- 14.7.3.2.4. By End User
15. Europe Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 15.1. Introduction
- 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 15.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 15.3.1. By Country
- 15.3.1.1. Germany
- 15.3.1.2. Italy
- 15.3.1.3. France
- 15.3.1.4. U.K.
- 15.3.1.5. Spain
- 15.3.1.6. BENELUX
- 15.3.1.7. Russia
- 15.3.1.8. Nordic Countries
- 15.3.1.9. Rest of Europe
- 15.3.2. By VEGF Types
- 15.3.3. By VGEF Application
- 15.3.4. By VGEF Expression Hosts
- 15.3.5. By End User
- 15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By VEGF Types
- 15.4.3. By VGEF Application
- 15.4.4. By VGEF Expression Hosts
- 15.4.5. By End User
- 15.5. Key Market Participants - Intensity Mapping
- 15.6. Drivers and Restraints - Impact Analysis
- 15.7. Country Level Analysis & Forecast
- 15.7.1. Germany Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.1.1. Introduction
- 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.1.2.1. By VEGF Types
- 15.7.1.2.2. By VGEF Application
- 15.7.1.2.3. By VGEF Expression Hosts
- 15.7.1.2.4. By End User
- 15.7.2. France Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.2.1. Introduction
- 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.2.2.1. By VEGF Types
- 15.7.2.2.2. By VGEF Application
- 15.7.2.2.3. By VGEF Expression Hosts
- 15.7.2.2.4. By End User
- 15.7.3. Italy Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.3.1. Introduction
- 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.3.2.1. By VEGF Types
- 15.7.3.2.2. By VGEF Application
- 15.7.3.2.3. By VGEF Expression Hosts
- 15.7.3.2.4. By End User
- 15.7.4. Spain Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.4.1. Introduction
- 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.4.2.1. By VEGF Types
- 15.7.4.2.2. By VGEF Application
- 15.7.4.2.3. By VGEF Expression Hosts
- 15.7.4.2.4. By End User
- 15.7.5. U.K. Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.5.1. Introduction
- 15.7.5.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.5.2.1. By VEGF Types
- 15.7.5.2.2. By VGEF Application
- 15.7.5.2.3. By VGEF Expression Hosts
- 15.7.5.2.4. By End User
- 15.7.6. Benelux Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.6.1. Introduction
- 15.7.6.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.6.2.1. By VEGF Types
- 15.7.6.2.2. By VGEF Application
- 15.7.6.2.3. By VGEF Expression Hosts
- 15.7.6.2.4. By End User
- 15.7.7. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.7.1. Introduction
- 15.7.7.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.7.2.1. By VEGF Types
- 15.7.7.2.2. By VGEF Application
- 15.7.7.2.3. By VGEF Expression Hosts
- 15.7.7.2.4. By End User
- 15.7.8. Russia Vascular Endothelial Growth Factor (VEGF) Market
- 15.7.8.1. Introduction
- 15.7.8.2. Market Analysis and Forecast by Market Taxonomy
- 15.7.8.2.1. By VEGF Types
- 15.7.8.2.2. By VGEF Application
- 15.7.8.2.3. By VGEF Expression Hosts
- 15.7.8.2.4. By End User
16. South Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 16.1. Introduction
- 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 16.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 16.3.1. By Country
- 16.3.1.1. India
- 16.3.1.2. Thailand
- 16.3.1.3. Indonesia
- 16.3.1.4. Malaysia
- 16.3.1.5. Rest of South Asia
- 16.3.2. By VEGF Types
- 16.3.3. By VGEF Application
- 16.3.4. By VGEF Expression Hosts
- 16.3.5. By End User
- 16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By VEGF Types
- 16.4.3. By VGEF Application
- 16.4.4. By VGEF Expression Hosts
- 16.4.5. By End User
- 16.5. Key Market Participants - Intensity Mapping
- 16.6. Drivers and Restraints - Impact Analysis
- 16.7. Country Level Analysis & Forecast
- 16.7.1. India Vascular Endothelial Growth Factor (VEGF) Market
- 16.7.1.1. Introduction
- 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.7.1.2.1. By VEGF Types
- 16.7.1.2.2. By VGEF Application
- 16.7.1.2.3. By VGEF Expression Hosts
- 16.7.1.2.4. By End User
- 16.7.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Market
- 16.7.2.1. Introduction
- 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.7.2.2.1. By VEGF Types
- 16.7.2.2.2. By VGEF Application
- 16.7.2.2.3. By VGEF Expression Hosts
- 16.7.2.2.4. By End User
- 16.7.3. Malaysia Vascular Endothelial Growth Factor (VEGF) Market
- 16.7.3.1. Introduction
- 16.7.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.7.3.2.1. By VEGF Types
- 16.7.3.2.2. By VGEF Application
- 16.7.3.2.3. By VGEF Expression Hosts
- 16.7.3.2.4. By End User
- 16.7.4. Thailand Vascular Endothelial Growth Factor (VEGF) Market
- 16.7.4.1. Introduction
- 16.7.4.2. Market Analysis and Forecast by Market Taxonomy
- 16.7.4.2.1. By VEGF Types
- 16.7.4.2.2. By VGEF Application
- 16.7.4.2.3. By VGEF Expression Hosts
- 16.7.4.2.4. By End User
17. East Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 17.1. Introduction
- 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 17.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 17.3.1. By Country
- 17.3.1.1. China
- 17.3.1.2. Japan
- 17.3.1.3. South Korea
- 17.3.2. By VEGF Types
- 17.3.3. By VGEF Application
- 17.3.4. By VGEF Expression Hosts
- 17.3.5. By End User
- 17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By VEGF Types
- 17.4.3. By VGEF Application
- 17.4.4. By VGEF Expression Hosts
- 17.4.5. By End User
- 17.5. Key Market Participants - Intensity Mapping
- 17.6. Drivers and Restraints - Impact Analysis
- 17.7. Country Level Analysis & Forecast
- 17.7.1. China Vascular Endothelial Growth Factor (VEGF) Market
- 17.7.1.1. Introduction
- 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.7.1.2.1. By VEGF Types
- 17.7.1.2.2. By VGEF Application
- 17.7.1.2.3. By VGEF Expression Hosts
- 17.7.1.2.4. By End User
- 17.7.2. Japan Vascular Endothelial Growth Factor (VEGF) Market
- 17.7.2.1. Introduction
- 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.7.2.2.1. By VEGF Types
- 17.7.2.2.2. By VGEF Application
- 17.7.2.2.3. By VGEF Expression Hosts
- 17.7.2.2.4. By End User
- 17.7.3. South Korea Vascular Endothelial Growth Factor (VEGF) Market
- 17.7.3.1. Introduction
- 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
- 17.7.3.2.1. By VEGF Types
- 17.7.3.2.2. By VGEF Application
- 17.7.3.2.3. By VGEF Expression Hosts
- 17.7.3.2.4. By End User
18. Oceania Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 18.1. Introduction
- 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 18.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 18.3.1. By Country
- 18.3.1.1. Australia
- 18.3.1.2. New Zealand
- 18.3.2. By VEGF Types
- 18.3.3. By VGEF Application
- 18.3.4. By VGEF Expression Hosts
- 18.3.5. By End User
- 18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By VEGF Types
- 18.4.3. By VGEF Application
- 18.4.4. By VGEF Expression Hosts
- 18.4.5. By End User
- 18.5. Key Market Participants - Intensity Mapping
- 18.6. Drivers and Restraints - Impact Analysis
- 18.7. Country Level Analysis & Forecast
- 18.7.1. Australia Vascular Endothelial Growth Factor (VEGF) Market
- 18.7.1.1. Introduction
- 18.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 18.7.1.2.1. By VEGF Types
- 18.7.1.2.2. By VGEF Application
- 18.7.1.2.3. By VGEF Expression Hosts
- 18.7.1.2.4. By End User
- 18.7.2. New Zealand Vascular Endothelial Growth Factor (VEGF) Market
- 18.7.2.1. Introduction
- 18.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 18.7.2.2.1. By VEGF Types
- 18.7.2.2.2. By VGEF Application
- 18.7.2.2.3. By VGEF Expression Hosts
- 18.7.2.2.4. By End User
19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031
- 19.1. Introduction
- 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
- 19.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
- 19.3.1. By Country
- 19.3.1.1. GCC Countries
- 19.3.1.2. Turkey
- 19.3.1.3. North Africa
- 19.3.1.4. South Africa
- 19.3.1.5. Rest of Middle East and Africa
- 19.3.2. By VEGF Types
- 19.3.3. By VGEF Application
- 19.3.4. By VGEF Expression Hosts
- 19.3.5. By End User
- 19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By VEGF Types
- 19.4.3. By VGEF Application
- 19.4.4. By VGEF Expression Hosts
- 19.4.5. By End User
- 19.5. Key Market Participants - Intensity Mapping
- 19.6. Drivers and Restraints - Impact Analysis
- 19.7. Country Level Analysis & Forecast
- 19.7.1. GCC Countries Vascular Endothelial Growth Factor (VEGF) Market
- 19.7.1.1. Introduction
- 19.7.1.2. Market Analysis and Forecast by Market Taxonomy
- 19.7.1.2.1. By VEGF Types
- 19.7.1.2.2. By VGEF Application
- 19.7.1.2.3. By VGEF Expression Hosts
- 19.7.1.2.4. By End User
- 19.7.2. Turkey Vascular Endothelial Growth Factor (VEGF) Market
- 19.7.2.1. Introduction
- 19.7.2.2. Market Analysis and Forecast by Market Taxonomy
- 19.7.2.2.1. By VEGF Types
- 19.7.2.2.2. By VGEF Application
- 19.7.2.2.3. By VGEF Expression Hosts
- 19.7.2.2.4. By End User
- 19.7.3. South Africa Vascular Endothelial Growth Factor (VEGF) Market
- 19.7.3.1. Introduction
- 19.7.3.2. Market Analysis and Forecast by Market Taxonomy
- 19.7.3.2.1. By VEGF Types
- 19.7.3.2.2. By VGEF Application
- 19.7.3.2.3. By VGEF Expression Hosts
- 19.7.3.2.4. By End User
- 19.7.4. North Africa Vascular Endothelial Growth Factor (VEGF) Market
- 19.7.4.1. Introduction
- 19.7.4.2. Market Analysis and Forecast by Market Taxonomy
- 19.7.4.2.1. By VEGF Types
- 19.7.4.2.2. By VGEF Application
- 19.7.4.2.3. By VGEF Expression Hosts
- 19.7.4.2.4. By End User
20. Market Structure Analysis
- 20.1. Market Analysis by Tier of Companies
- 20.2. Market Share Analysis of Top Players
- 20.3. Market Presence Analysis
- 20.3.1. By Regional footprint of Players
- 20.3.2. Device foot print by Players
- 20.3.3. Channel Foot Print by Players
21. Competition Analysis
- 21.1. Competition Dashboard
- 21.2. Competition Benchmarking
- 21.3. Competition Deep Dive
- 21.3.1. Thermo Fisher Scientific
- 21.3.1.1. Overview & Key financials
- 21.3.1.2. Product Portfolio
- 21.3.1.3. Key Financials
- 21.3.1.4. Sales Footprint
- 21.3.1.5. SWOT Analysis
- 21.3.1.6. Analysis Commentary
- 21.3.1.7. Strategy Overview
- 21.3.2. Merck KGaA
- 21.3.2.1. Overview & Key financials
- 21.3.2.2. Product Portfolio
- 21.3.2.3. Key Financials
- 21.3.2.4. Sales Footprint
- 21.3.2.5. SWOT Analysis
- 21.3.2.6. Analysis Commentary
- 21.3.2.7. Strategy Overview
- 21.3.3. Bio-Rad Laboratories, Inc.
- 21.3.3.1. Overview & Key financials
- 21.3.3.2. Product Portfolio
- 21.3.3.3. Key Financials
- 21.3.3.4. Sales Footprint
- 21.3.3.5. SWOT Analysis
- 21.3.3.6. Analysis Commentary
- 21.3.3.7. Strategy Overview
- 21.3.4. Bio-Techne [R&D Systems, Inc.]
- 21.3.4.1. Overview & Key financials
- 21.3.4.2. Product Portfolio
- 21.3.4.3. Key Financials
- 21.3.4.4. Sales Footprint
- 21.3.4.5. SWOT Analysis
- 21.3.4.6. Analysis Commentary
- 21.3.4.7. Strategy Overview
- 21.3.5. GenScript
- 21.3.5.1. Overview & Key financials
- 21.3.5.2. Product Portfolio
- 21.3.5.3. Key Financials
- 21.3.5.4. Sales Footprint
- 21.3.5.5. SWOT Analysis
- 21.3.5.6. Analysis Commentary
- 21.3.5.7. Strategy Overview
- 21.3.6. Miltenyi Biotec.
- 21.3.6.1. Overview & Key financials
- 21.3.6.2. Product Portfolio
- 21.3.6.3. Key Financials
- 21.3.6.4. Sales Footprint
- 21.3.6.5. SWOT Analysis
- 21.3.6.6. Analysis Commentary
- 21.3.6.7. Strategy Overview
- 21.3.7. Abcam PLC.
- 21.3.7.1. Overview & Key financials
- 21.3.7.2. Product Portfolio
- 21.3.7.3. Key Financials
- 21.3.7.4. Sales Footprint
- 21.3.7.5. SWOT Analysis
- 21.3.7.6. Analysis Commentary
- 21.3.7.7. Strategy Overview
- 21.3.8. Sino Biological Inc.
- 21.3.8.1. Overview & Key financials
- 21.3.8.2. Product Portfolio
- 21.3.8.3. Key Financials
- 21.3.8.4. Sales Footprint
- 21.3.8.5. SWOT Analysis
- 21.3.8.6. Analysis Commentary
- 21.3.8.7. Strategy Overview
- 21.3.9. Cell Signaling Technology, Inc.
- 21.3.9.1. Overview & Key financials
- 21.3.9.2. Product Portfolio
- 21.3.9.3. Key Financials
- 21.3.9.4. Sales Footprint
- 21.3.9.5. SWOT Analysis
- 21.3.9.6. Analysis Commentary
- 21.3.9.7. Strategy Overview
- 21.3.10. ACROBiosystems
- 21.3.10.1. Overview & Key financials
- 21.3.10.2. Product Portfolio
- 21.3.10.3. Key Financials
- 21.3.10.4. Sales Footprint
- 21.3.10.5. SWOT Analysis
- 21.3.10.6. Analysis Commentary
- 21.3.10.7. Strategy Overview
- 21.3.11. STEMCELL Technologies
- 21.3.11.1. Overview & Key financials
- 21.3.11.2. Product Portfolio
- 21.3.11.3. Key Financials
- 21.3.11.4. Sales Footprint
- 21.3.11.5. SWOT Analysis
- 21.3.11.6. Analysis Commentary
- 21.3.11.7. Strategy Overview
- 21.3.12. Creative Bioarray
- 21.3.12.1. Overview & Key financials
- 21.3.12.2. Product Portfolio
- 21.3.12.3. Key Financials
- 21.3.12.4. Sales Footprint
- 21.3.12.5. SWOT Analysis
- 21.3.12.6. Analysis Commentary
- 21.3.12.7. Strategy Overview
- 21.3.13. PeproTech
- 21.3.13.1. Overview & Key financials
- 21.3.13.2. Product Portfolio
- 21.3.13.3. Key Financials
- 21.3.13.4. Sales Footprint
- 21.3.13.5. SWOT Analysis
- 21.3.13.6. Analysis Commentary
- 21.3.13.7. Strategy Overview
- 21.3.14. Applied Biological Materials (abm) Inc.
- 21.3.14.1. Overview & Key financials
- 21.3.14.2. Product Portfolio
- 21.3.14.3. Key Financials
- 21.3.14.4. Sales Footprint
- 21.3.14.5. SWOT Analysis
- 21.3.14.6. Analysis Commentary
- 21.3.14.7. Strategy Overview
- 21.3.15. GenWay Biotech
- 21.3.15.1. Overview & Key financials
- 21.3.15.2. Product Portfolio
- 21.3.15.3. Key Financials
- 21.3.15.4. Sales Footprint
- 21.3.15.5. SWOT Analysis
- 21.3.15.6. Analysis Commentary
- 21.3.15.7. Strategy Overview
- 21.3.16. Leadgene Biomedical, Inc.
- 21.3.16.1. Overview & Key financials
- 21.3.16.2. Product Portfolio
- 21.3.16.3. Key Financials
- 21.3.16.4. Sales Footprint
- 21.3.16.5. SWOT Analysis
- 21.3.16.6. Analysis Commentary
- 21.3.16.7. Strategy Overview
- 21.3.17. Boster Bio
- 21.3.17.1. Overview & Key financials
- 21.3.17.2. Product Portfolio
- 21.3.17.3. Key Financials
- 21.3.17.4. Sales Footprint
- 21.3.17.5. SWOT Analysis
- 21.3.17.6. Analysis Commentary
- 21.3.17.7. Strategy Overview
- 21.3.18. Prospec-Tany Technogene Ltd.
- 21.3.18.1. Overview & Key financials
- 21.3.18.2. Product Portfolio
- 21.3.18.3. Key Financials
- 21.3.18.4. Sales Footprint
- 21.3.18.5. SWOT Analysis
- 21.3.18.6. Analysis Commentary
- 21.3.18.7. Strategy Overview
- 21.3.19. Proteintech Group, Inc
- 21.3.19.1. Overview & Key financials
- 21.3.19.2. Product Portfolio
- 21.3.19.3. Key Financials
- 21.3.19.4. Sales Footprint
- 21.3.19.5. SWOT Analysis
- 21.3.19.6. Analysis Commentary
- 21.3.19.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology